pembrolizumab
merck
['nsclc', 'lung', 'sclc', 'pearls', 'pearl', 'keynote,91', 'pembro']
presenting now at #esmo22: interim analysis of pearls/keynote-091 - #pembrolizumab vs placebo as #adjuvant therapy for completely resected stage ib iiia non-small-cell #lungcancer #nsclc 
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=54.433